Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 3, Number 1—March 1997

Synopsis

Infectious Diseases and Immunity: Special Reference to Major Histocompatibility Complex

Neeloo Singh*Comments to Author , S. Agrawal†, and A.K. Rastogi*
Author affiliations: *Department of Biochemistry, Central Drug Research Institute, Lucknow, India; †Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Main Article

Table 1

Frequency of HLA class II alleles with significant differences between leprosy patients and healthy controls

Healthy controls
Leprosy patients
HLA alleles N=47
N=93
N % N % RRa p
DRB1*15 10 21.3 70 75.3 11.3 <0.00001
DRB1*1501 6 12.8 49 52.7 7.6 <0.00001
DRB1*1502 5 10.6 26 27.9 3.2 <0.05
DRB5*0101 6 12.8 49 52.7 7.6 <0.00001
DRB5*0102 5 10.6 26 27.9 3.2 <0.05
DQA1*0102 9 19.1 38 40.9 2.9 <0.05
DQA1*0103 13 27.6 48 51.6 2.8 <0.05
DQB1*0601 8 17.0 56 60.2 7.4 <0.00001
DRB1*0404 5 10.6 0 0.0 0.04 <0.01
DRB1*0701 13 29.8 11 11.8 0.3 <0.05
DRB1*1401 4 8.5 0 0.0 0.005 <0.05
DQB1*0503 16 36.2 14 16.1 0.3 <0.05

aRR = relative risk

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO